Anti-Infective Agents Market Share, Size and Growth Analysis By 2029

The market for anti-infective agents is projected to expand from approximately US$ 135,961.03 million in 2022 to around US$ 164,196.61 million by 2028, reflecting a compound annual growth rate (CAGR) of 3.19% during the period from 2022 to 2028.

Anti-infectives are a class of medications designed to prevent and treat infections, encompassing various types such as anti-bacterial, anti-viral, anti-fungal, and antiparasitic drugs. These therapeutic agents play a crucial role in managing both minor infections and severe infectious diseases, including conditions like tuberculosis and pneumonia. The advent of anti-infective therapies has significantly transformed healthcare, enhancing the quality of life and longevity for patients afflicted with diverse infectious diseases.

Chronic diseases, which develop over an extended timeframe, arise from a complex interplay of genetic, physiological, environmental, and lifestyle factors. The World Health Organization (WHO) categorizes noncommunicable diseases (NCDs) into four main groups: diabetes, cancer, chronic respiratory diseases (such as chronic obstructive pulmonary disease and asthma), and cardiovascular diseases (including heart attacks and strokes). NCDs are responsible for approximately 41 million deaths annually, accounting for 71% of all global fatalities. Alarmingly, over 15 million individuals aged between 30 and 69 succumb to NCDs each year, with 85% of these premature deaths occurring in low- and middle-income countries. Cardiovascular diseases lead the statistics, causing around 17.9 million deaths annually, followed by cancers (9.3 million), respiratory diseases (4.1 million), and diabetes (1.5 million).

The increasing prevalence of anti-infective resistance has emerged as a significant global public health challenge, threatening human health on multiple fronts. Anti-infective drugs, including antibiotics, antivirals, antifungals, and antiparasitics, are essential for combating infections. Antibiotics, in particular, are synthetic antimicrobial agents that treat and prevent bacterial infections by either killing bacteria or inhibiting their growth. Notable examples of antibiotics include macrolides such as azithromycin, clarithromycin, and erythromycin, which have historically been pivotal in treating bacterial infections and have been investigated for their potential in secondary prevention of coronary heart diseases.

The anti-infective agents market is categorized based on the route of administration, which includes topical, oral, intravenous (IV), and other methods. As of 2022, the IV segment commands the largest market share. Patients suffering from bacterial infections often require antibiotic treatment, with the oral route being the most common choice. However, intravenous administration is frequently preferred for hospitalized patients. The necessity for IV administration is particularly high in cases where patients are unable to swallow or absorb oral medications, or when microbial susceptibility necessitates the use of an effective agent with poor oral bioavailability. Additionally, IV administration is recommended for severe, life-threatening infections or deep-seated infections to ensure adequate antibiotic concentrations at the infection site.

In terms of indications, the anti-infective agents market is divided into segments such as HIV, tuberculosis, respiratory infections, pneumonia, and others. The HIV segment is anticipated to hold the largest market share in 2022. HIV, or human immunodeficiency virus, compromises the immune system by destroying critical cells that combat disease and infection. Certain demographics in the United States are at a heightened risk of contracting HIV due to factors such as sexual behavior and partner dynamics. The risk of postoperative infections can increase due to the immune suppression caused by HIV. The number of individuals living with HIV has been on the rise, and the introduction of antiretroviral therapy (ART) has significantly improved the life expectancy of those with HIV and AIDS. Consequently, the demand for surgical interventions and the prevalence of surgical conditions related to HIV continue to grow. Persistent immunological abnormalities, despite successful HIV replication suppression through ART, highlight the ongoing health challenges faced by these patients.

In preparing the report on the anti-infective agents market, several key primary and secondary sources were consulted, including the World Health Organization (WHO), the European Federation of Pharmaceutical Industries and Associations, and the Centers for Disease Control and Prevention (CDC).